Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Cao Website

Liang Cao, Ph.D.

Selected Publications

1)  Giaccone G, Rajan A, Berman A, Kelly R, Szabo E, Lopez-Chavez A, Trepel J, Lee M, Cao L, Espinoza-Delgado I, Spittler J, Loehrer P.
Belinostat phase II study in patients with recurrent or refractory advanced thymic epithelial tumors.
J Clin Oncol. 2014.
In Press. [Journal]
2)  Mayeenuddin L, Yu Y, Kang Z, Helman L, Cao L.
Insulin-like growth factor 1 receptor antibody induces rhabdomyoscarcoma cell death via a process involving AKT and Bcl-x(L).
Oncogene. 2014.
In Press. [Journal]
3)  Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS.
Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer.
Cancer Res. 70: 6497-508, 2010.
4)  Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao L, Burger AM, Ziche M, Melillo G.
Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.
Cancer Res. 70: 6837-48, 2010.
5)  Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
J. Clin. Oncol. 26: 3709-14, 2008.
6)  Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, Helman LJ.
Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
Cancer Res. 68: 8039-48, 2008.
7)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 2014.
8)  Harouaka R, Kang Z, Zheng S, Cao L.
Circulating tumor cells: Advances in isolation and analysis, and challenges for clinical applications.
Pharmacol. Ther. 2013.
9)  Kang Z, Yu Y, Zhu YJ, Davis S, Walker R, Meltzer PS, Helman LJ, Cao L.
Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
Oncogene. 2013.
10)  Kang Z, Sun SY, Cao L.
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.
ISRN Oncol. 2012: 395952, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 3/31/2014.